relative to prescription drug affordability board conflicts of interest.

HB 1225 establishes stricter rules for conflicts of interest for members, staff, and contractors of the Prescription Drug Affordability Board and its advisory council. The bill requires individuals to recuse themselves from decisions if they or their close associates have financial ties to drug manufacturers or could personally benefit from the board's work, while also mandating public disclosure of any such conflicts. It further prohibits accepting gifts that could create an appearance of bias and allows for the immediate removal of board members who violate these rules. Although the bill was referred for an interim study, the committee ultimately recommended against pursuing it as future legislation.